Morgan Stanley Assumes BeiGene, Ltd. (BGNE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
BeiGene, Ltd. (BGNE) PT Raised to $207 at Bernstein SocGen Group
November 29, 2024 8:35 AM ESTBernstein SocGen Group analyst Rebecca Liang raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $207.00 while maintaining a Market Perform rating.
The analyst said: "In this model update of BeiGene post-earnings, we present a new, integrated B-cell malignancies market model covering... More
